SCHEMBL459485

SCHEMBL459485

O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1302305 1.00
SCHEMBL23041319 1.00
SCHEMBL9499195 0.97
SCHEMBL3857933 0.82 AKR1B1 (0.37)
SCHEMBL31611656 0.82 AKR1B1 (0.37)
SCHEMBL23072256 0.82 AKR1B1 (0.37)
SCHEMBL1547638 0.82 AKR1B1 (0.37)
SCHEMBL15329241 0.77 AKR1B1 (0.30)
SCHEMBL21598343 0.77 AKR1B1 (0.30)
SCHEMBL12396667 0.75 AKR1B1 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4438734-A2 REPROGRAMMING OF CELLS TO A NEW FATE The Scripps Research Institute (US) 2024-10-02 EP disclosed
EP-3399026-B1 REPROGRAMMING OF CELLS TO A NEW FATE SCRIPPS RESEARCH INST (US) 2024-06-26 EP disclosed
US-20220296722-A1 CONJUGATES AND CONJUGATES FOR USE IN PREVENTING OR TREATING OF BRAIN DAMAGE AND NEURODEGENERATIVE DISEASES MEDICORTEX FINLAND OY (FI) 2022-09-22 US disclosed
EP-4021510-A2 CONJUGATES AND CONJUGATES FOR USE IN PREVENTING OR TREATING OF BRAIN DAMAGE AND NEURODEGENERATIVE DISEASES Medicortex Finland Oy (FI) 2022-07-06 EP disclosed
US-20210189348-A1 REPROGRAMMING OF CELLS TO A NEW FATE THE SCRIPPS RESEARCH INSTITUTE 2021-06-24 US disclosed
WO-2021038125-A2 CONJUGATES AND CONJUGATES FOR USE IN PREVENTING OR TREATING OF BRAIN DAMAGE AND NEURODEGENERATIVE DISEASES MEDICORTEX FINLAND OY (FI) 2021-03-04 WO disclosed
US-10934528-B2 Reprogramming of cells to a new fate THE SCRIPPS RESEARCH INSTITUTE (US) 2021-03-02 US disclosed
US-10308912-B2 Reprogramming of cells to a new fate THE SCRIPPS RESEARCH INSTITUTE (US) 2019-06-04 US disclosed
EP-3399026-A1 REPROGRAMMING OF CELLS TO A NEW FATE The Scripps Research Institute (US) 2018-11-07 EP disclosed
EP-2580320-B1 REPROGRAMMING OF CELLS TO A NEW FATE SCRIPPS RESEARCH INST (US) 2018-08-01 EP disclosed
US-20090324682-A1 Medical stent provided with inhibitors of atp synthesis INTERSTITIAL THERAPEUTICS (CH) 2009-12-31 US disclosed
EP-1789107-B1 MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS INTERSTITIAL THERAPEUTICS (CH) 2009-05-27 EP disclosed
US-20070293439-A1 Methods and Compositions for Treating Hyperglycemic, Hyperlipidemic, or Hyperinsulinemic Disorders OHIO UNIVERSITY (US) 2007-12-20 US disclosed
US-20070292478-A1 Medical Implant Provided with Inhibitors of Atp Synthesis INTERSTITIAL THERAPEUTICS (CH) 2007-12-20 US disclosed
EP-1789030-A2 MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS Interstitial Therapeutics (CH) 2007-05-30 EP disclosed
EP-1789107-A2 MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS Interstitial Therapeutics (CH) 2007-05-30 EP disclosed
WO-2006034468-A9 METHODS AND COMPOSITIONS FOR TREATING HYPERGLYCEMIC, HYPERLIPIDEMIC, OR HYPERINSULINEMIC DISORDERS UNIV OHIO (US) 2006-07-27 WO disclosed
WO-2006034468-A2 METHODS AND COMPOSITIONS FOR TREATING HYPERGLYCEMIC, HYPERLIPIDEMIC, OR HYPERINSULINEMIC DISORDERS OHIO UNIVERSITY (US) 2006-03-30 WO disclosed
WO-2006024488-A2 MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS INTERSTITIAL THERAPEUTICS (CH) 2006-03-09 WO disclosed
WO-2006024492-A2 MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS INTERSTITIAL THERAPEUTICS (CH) 2006-03-09 WO disclosed